Parafibromin Staining Characteristics in Urothelial Carcinomas and Relationship with Prognostic Parameters
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Parafibromin is a recently defined tumor suppressor gene. The aim of our study was to determine the relationships of parafibromin expression in urothelial carcinomas (UCs) with prognostic parameters and to evaluate the use of parafibromin as a potential marker of UC. Methods: Parafibromin expression was assessed in 49 UC specimens using immunohistochemistry. The correlations between parafibromin expression and clinical and pathologic parameters were investigated. Results: Of the patients, 42 (85.7%) were male, and the mean age was 69.6 ± 8.2 years (range, 54 to 88 years). Morphologically, the UCs were divided into two groups: papillary (n = 27) and non-papillary (n = 22). There were seven low-grade (14.3%) and 42 high-grade (85.7%) tumors. Parafibromin was negative in 13 tumors (26.5%), partially positive in 19 tumors (38.8%), and positive in 17 tumors (34.7%). Parafibromin expression was more negative in UCs from upper urinary locations (n = 17) and with muscularis propria invasion (n = 28), which was statistically significant (p = .009 and p = .007, respectively). There was no statistically significant relationship between parafibromin expression and gender, age, tumor grade, survival, or disease-free survival. Conclusions: We found that UC cases with parafibromin positivity had less of a tendency to show muscularis propria invasion and were more commonly located in the lower urinary system. These results need to be confirmed with studies based on larger case series.
Abstract
Background: Parafibromin is a recently defined tumor suppressor gene. The aim of our study was to determine the relationships of parafibromin expression in urothelial carcinomas (UCs) with prognostic parameters and to evaluate the use of parafibromin as a potential marker of UC. Methods: Parafibromin expression was assessed in 49 UC specimens using immunohistochemistry. The correlations between parafibromin expression and clinical and pathologic parameters were investigated. Results: Of the patients, 42 (85.7%) were male, and the mean age was 69.6 ± 8.2 years (range, 54 to 88 years). Morphologically, the UCs were divided into two groups: papillary (n = 27) and non-papillary (n = 22). There were seven low-grade (14.3%) and 42 high-grade (85.7%) tumors. Parafibromin was negative in 13 tumors (26.5%), partially positive in 19 tumors (38.8%), and positive in 17 tumors (34.7%). Parafibromin expression was more negative in UCs from upper urinary locations (n = 17) and with muscularis propria invasion (n = 28), which was statistically significant (p = .009 and p = .007, respectively). There was no statistically significant relationship between parafibromin expression and gender, age, tumor grade, survival, or disease-free survival. Conclusions: We found that UC cases with parafibromin positivity had less of a tendency to show muscularis propria invasion and were more commonly located in the lower urinary system. These results need to be confirmed with studies based on larger case series.
참고문헌 (27)
- Ploeg M, "The present and future burden of urinary bladder cancer in the world", World J Urol, 27, pp.289~293 (2009)
- Jemal A, "Cancer statistics, 2009", CA Cancer J Clin, 59, pp.225~249 (2009)
- Margulis V, "Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration", Cancer, 115, pp.1224~1233 (2009)
- Oldbring J, "Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings", J Urol, 141, pp.1311~1313 (1989)
- Babjuk M, "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder", Eur Urol, 54, pp.303~314 (2008)
- Hall MC, "Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients", Urology, 52, pp.594~601 (1998)
- Olgac S, "Urothelial carcinoma of the renal pelvis : a clinicopathologic study of 130 cases", Am J Surg Pathol, 28, pp.1545~1552 (2004)
- Faraj SF, "ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder", Hum Pathol, 45, pp.2233~2239 (2014)
- Ramos Soler D, "Multiple analysis of morphologic factors with prognostic value in transitional cell papillary carcinoma of the bladder. Retrospective study of 571 cases", Actas Urol Esp, 23, pp.119~126 (1999)
- Schapers RF, "A simplified grading method of transitional cell carcinoma of the urinary bladder: reproducibility, clinical significance and comparison with other prognostic parameters", Br J Urol, 73, pp.625~631 (1994)
- Aldred MJ, "Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 101, pp.212~218 (2006)
- Pimenta FJ, "HRPT2 gene alterations in ossifying fibroma of the jaws", Oral Oncol, 42, pp.735~739 (2006)
- Shattuck TM, "Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma", N Engl J Med, 349, pp.1722~1729 (2003)
- Carpten JD, "HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome", Nat Genet, 32, pp.676~680 (2002)
- Wang PF, "HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome", Horm Metab Res, 37, pp.380~383 (2005)
- Cetani F, "Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?", Eur J Endocrinol, 156, pp.547~554 (2007)
- Gill AJ, "Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor(HPT-JT)syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias", Am J Surg Pathol, 30, pp.1140~1149 (2006)
- Selvarajan S, "Parafibromin expression in breast cancer: a novel marker for prognostication?", J Clin Pathol, 61, pp.64~67 (2008)
- Tan MH, "Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma", Clin Cancer Res, 10, pp.6629~6637 (2004)
- Zheng HC, "Parafibromin expression is an independent prognostic factor for colorectal carcinomas", Hum Pathol, 42, pp.1089~1102 (2011)
- Zheng HC, "Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas", Virchows Arch, 452, pp.147~155 (2008)
- Eble JN, "World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs", pp.90~ (2004), IARC Press
- Quek ML, "Natural history of surgically treated bladder carcinoma with extravesical tumor extension", Cancer, 98, pp.955~961 (2003)
- Tilki D, "Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy : an international study of 243 patients", J Urol, 183, pp.1757~1763 (2010)
- Kim SH, "A retrospective analysis of incidence and its associated risk factors of upper urinary tract recurrence following radical cystectomy for bladder cancer with transitional cell carcinoma: the significance of local pelvic recurrence and positive lymph node", PLoS One, 9, pp.e96467~ (2014)
- Rausch S, "Nonbilharzial squamous cell carcinoma and transitional cell carcinoma with squamous differentiation of the lower and upper urinary tract", Urol Ann, 4, pp.14~18 (2012)
- Porzionato A, "Immunohistochemical assessment of parafibromin in mouse and human tissues", J Anat, 209, pp.817~827 (2006)